Secukinumab (anti-IL-17A)

Catalog No.A2025 Synonyms: Cosentyx, AIN457

For research use only.
Not for use in humans.

Secukinumab (anti-IL-17A) (Cosentyx, AIN457) is a human IgG1κ monoclonal antibody that binds to the protein interleukin (IL)-17A, and is applied for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. MW=147.9 kDa.

Cited by 1 publication

Quality Control

Choose Selective Interleukins Inhibitors

Biological Activity

Description Secukinumab (anti-IL-17A) (Cosentyx, AIN457) is a human IgG1κ monoclonal antibody that binds to the protein interleukin (IL)-17A, and is applied for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. MW=147.9 kDa.
In vitro

Healthy donors show both significantly less frequent T cell responses and lower numbers of pre-existing T cells to Secukinumab than other approved therapeutic antibodies used to treat plaque psoriasis.[1]

In vivo

The validation study using secukinumab shows similar results to the DSS-induced colitis model in Il17a−/− mice. WT mice that received secukinumab tend to lose less weight than those who do not. In the validation study using secukinumab, chronic colitis is induced in all the Rag2−/− mice that received T cells. Although statistical significance is not achieved in the comparison between the T cell transfer with secukinumab group and the group that does not receive secukinumab due to a small sample size, administration of secukinumab can not attenuate chronic colitis.[2]

Protocol

Cell Research:
- Collapse
  • Objective: T Cell Assay
    Cells: Dendritic cells
    Concentrations: 1 μM
    Incubation Time: overnight
    Method: Dendritic cells (DC) are produced from plastic-adherent cells of PBMCs while CD4 T cells are isolated from PBMCs by using magnetic microbeads. The quality of the DCs is assessed by labelling of markers HLA-DR, HLA-A,B,C, CD14, DC-SIGN, CD86 and CD80. DCs are separately loaded overnight at 37 °C with keyhole limpet hemocyanin, KLH, used as a positive control (0.25 µM), or with the therapeutic antibodies secukinumab (1 µM) and matured with lipopolysaccharide (1 µg/mL). CD4 T cells (200 000/well) are stimulated by protein-loaded DCs (20,000/well) and cultured during 21 days. The number of antigen specific T cells is identified by interferon gamma (IFN-γ) ELISpot assay using an AID ELISpot Reader System.
    Reference: https://pubmed.ncbi.nlm.nih.gov/29392570

    Secukinumab can apply to humanized mice, non-humanized mice (eg: C57BL/6 mice), peripheral blood and other related assays (Only for Reference)

Animal Research:
- Collapse
  • Objective: The validation study
    Animal Models: WT C57BL/6 mice
    Formulation: DSS
    Dosages: 100 μL
    Administration: i.p.
    Reference: https://pubmed.ncbi.nlm.nih.gov/31941937

    Secukinumab can apply to humanized mice, non-humanized mice (eg: C57BL/6 mice), peripheral blood and other related assays (Only for Reference)

Product Details

CAS No. 1229022-83-6
Formulation PBS buffer, pH 7.2
Isotype Human IgG1
Source Human
Storage Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Tech Support

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
Tags: buy Secukinumab (anti-IL-17A) | Secukinumab (anti-IL-17A) supplier | purchase Secukinumab (anti-IL-17A) | Secukinumab (anti-IL-17A) cost | Secukinumab (anti-IL-17A) manufacturer | order Secukinumab (anti-IL-17A) | Secukinumab (anti-IL-17A) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID